LabConnect, LLC, a leading global provider of central laboratory and support services for biopharmaceutical, medical device and contract research organizations, has completed phase one of an 11,000+ square foot facility expansion in Johnson City, Tennessee. The new space will significantly increase the capacity for peripheral blood mononuclear cell (PBMC) processing and allow LabConnect to better serve its clients.
As a response to its 30 percent growth since 2017, LabConnect’s facility expansion is essential to serving increasingly complex studies and the related demand for corresponding services. Phase one expanded the company’s clinical sample kit-building and storage capabilities. Phase two of the facility upgrade will add more offices and project management space, while phase three will build out the PBMC laboratory capabilities.
“We have grown every year since our founding in 2002, and we are committed to maintaining our facilities with cutting-edge technology,” said Eric Hayashi, president and CEO of LabConnect. “It is an exciting time to be building our business, constantly improving sample testing services to meet clients’ needs and helping to save lives while supporting clinical trials.”
LabConnect’s expansion will be complete in September 2018. A detailed moving plan has been developed to ensure seamless business continuity, regulatory compliance and sample integrity.
For more information, visit labconnectllc.com.
No comments:
Post a Comment